Earnings Call · Q2 FY2021·2021-08-05

Q2 21EPS -64.52%·Rev n/aQ1 21EPS -25.00%·Rev n/aQ4 20EPS -50.00%·Rev n/aQ3 20EPS -75.00%·Rev n/a⚠ consensus missing

Akebia Therapeutics, Inc. AKBA

Kristen Sheppard — Senior Vice President of Investor Relations

John Butler — President and Chief Executive Officer

David Spellman — Chief Financial Officer

+15.7%1d on move date+15.1% vs SPY3d+10.1%5d+3.6%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AKBA calls or request research access.

More AKBA calls Browse calls Request research access